Effect of Autologous Platelet-Rich Plasma Intrauterine Infusion on the Clinical Outcomes of Freeze-Thawed Embryo Transfer Cycles in Patients With Atypical Recurrent Implantation Failure

Background: Atypical recurrent implantation failure (RIF) poses a challenge for freeze-thawed embryo transfer (FET) as current interventions showing limited efficacy. Autologous platelet-rich plasma (PRP) may improve the pregnancy outcomes, but its value before FET in such patients remains unclear. Methods: A retrospective analysis was conducted on the medical records of patients with atypical RIF (a history of one or two prior failed embryo transfers) who underwent another FET in Reproductive Medicine Center of Zhongda Hospital between January 1, 2022, and June 1, 2024. Patients who received autologous PRP intrauterine infusion before FET were designated as the PRP group (n = 59), while matched patients from the same period who did not receive PRP served as the control group (n = 79). The two groups were compared for endometrial thickness on the day of embryo transfer, biochemical pregnancy rate, embryo implantation rate, clinical pregnancy rate, and early miscarriage rate. Results: No statistically significant differences were observed in the baseline characteristics between the control and PRP groups (all p > 0.05). The PRP group had a significantly higher biochemical pregnancy rate (66.10% vs. 45.57%), embryo implantation rate (43.75% vs. 30.83%), and clinical pregnancy rate (57.63% vs. 39.24%) compared to the control group (p < 0.05). Conclusions: For patients with atypical RIF, intrauterine infusion with autologous PRP can increase the embryo implantation and clinical pregnancy rates in subsequent FET cycles.